- Home
- LWAY vs IGMS Comparison
LWAY vs IGMS Comparison
Compare LWAY & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAY
- IGMS
- Stock Information
- Founded
- LWAY 1986
- IGMS 1993
- Country
- LWAY United States
- IGMS United States
- Employees
- LWAY N/A
- IGMS N/A
- Industry
- LWAY Packaged Foods
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- LWAY Consumer Staples
- IGMS Health Care
- Exchange
- LWAY Nasdaq
- IGMS Nasdaq
- Market Cap
- LWAY N/A
- IGMS 82.1M
- IPO Year
- LWAY 1987
- IGMS 2019
- Fundamental
- Price
- LWAY $20.42
- IGMS $1.29
- Analyst Decision
- LWAY Hold
- IGMS Hold
- Analyst Count
- LWAY 1
- IGMS 8
- Target Price
- LWAY N/A
- IGMS $6.14
- AVG Volume (30 Days)
- LWAY 33.9K
- IGMS 226.3K
- Earning Date
- LWAY 03-19-2025
- IGMS 03-06-2025
- Dividend Yield
- LWAY N/A
- IGMS N/A
- EPS Growth
- LWAY 59.90
- IGMS N/A
- EPS
- LWAY 0.86
- IGMS N/A
- Revenue
- LWAY $181,979,000.00
- IGMS $2,679,000.00
- Revenue This Year
- LWAY $19.70
- IGMS $134.71
- Revenue Next Year
- LWAY $8.57
- IGMS $74.27
- P/E Ratio
- LWAY $23.97
- IGMS N/A
- Revenue Growth
- LWAY 18.27
- IGMS 25.77
- 52 Week Low
- LWAY $10.06
- IGMS $1.19
- 52 Week High
- LWAY $28.61
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- LWAY 35.99
- IGMS 32.10
- Support Level
- LWAY $20.27
- IGMS $1.26
- Resistance Level
- LWAY $21.87
- IGMS $1.43
- Average True Range (ATR)
- LWAY 0.97
- IGMS 0.11
- MACD
- LWAY -0.03
- IGMS 0.10
- Stochastic Oscillator
- LWAY 24.46
- IGMS 40.71
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.